Thiolated chitosan as an intestinal absorption carrier with hesperidin encapsulation for obesity treatment
Journal
Nutrients
Journal Volume
13
Journal Issue
12
Date Issued
2021
Author(s)
Abstract
Obesity is characterized as abnormal or excessive fat accumulation harmful to one’s health, linked to hormonal imbalances, cardiovascular illness, and coronary artery disease. Since the disease stems mainly from overconsumption, studies have aimed to control intestinal absorption as a route for treatment. In this study, chitosan-thioglycolic acid (CT) was developed as a physical barrier in the gastrointestinal tracts to inhibit nutrient uptake. CT exhibits a superior mucoadhesive property compared to chitosan both in vitro and in vivo for the ability to form disulfide bonds with the intestinal mucosa. For CT as a potential drug delivery platform, hesperidin, a herb for bodyweight control in traditional Chinese medication, is encapsulated in CT and can be released consistently from this absorption barrier. In animal studies, CT encapsulated with hesperidin (CTH) not only results in a weight-controlling effect but limits adipose accumulation by hindering absorption, suggesting a potential role in obesity treatment. Neither CT nor CTH exhibit cytotoxicity or produce adverse immunological reactions in vivo. ? 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Subjects
Chitosan
Hesperidin
Obesity
Thiol
2-mercaptoacetate
chitosan
disulfide
hesperidin
thioglycolic acid
animal
C57BL mouse
cell culture
drug delivery system
drug effects
gastrointestinal tract
in vitro study
intestine absorption
intestine mucosa
male
metabolism
obesity
Animals
Cells, Cultured
Disulfides
Drug Delivery Systems
Gastrointestinal Tract
In Vitro Techniques
Intestinal Absorption
Intestinal Mucosa
Male
Mice, Inbred C57BL
Nutrients
Thioglycolates
SDGs
Type
journal article